Immunotherapy
Conference Coverage
Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest
Cancer patients treated with immune checkpoint inhibitors are not significantly more likely to develop or die from COVID-19, two studies suggest...
From the Journals
Real-world results with checkpoint inhibitors found inferior to trial results
Data suggest real-world survival is worse than survival in clinical trials.
Conference Coverage
Lower BP and better tumor control with drug combo?
Conference Coverage
Lenvatinib combo may offer hope after immunotherapy in melanoma
Conference Coverage
The march of immunotherapy continues at ESMO 2020
From the Journals
Immunotherapy should not be withheld because of sex, age, or PS
News from the FDA/CDC
FDA approves new indications for pembrolizumab
Conference Coverage
Personalized cancer vaccine may enhance checkpoint inhibitor activity
Conference Coverage
New registry focuses on rheumatic immune-related AEs of cancer therapy
Data from the German TRheuMa registry suggest these events are generally mild or moderate, verifiable by CRP level and imaging (but not...
News
FDA approves immunotherapy combo for liver cancer
Conference Coverage
Cancer increase observed in modern era of MS drugs
WEST PALM BEACH, FLA. – The increased incidence is observed post 1996; the risk is nevertheless called small.